CHAIR program will deal with the development of new technologies and applications of the C-H activation field to promote its wider implementation in industry

9 academic groups

Academia (11 PhD Positions):
– Prof. L. Ackermann, Göttingen, Germany
– Prof. D. Gryko, Warsaw, Poland
– Prof. A. Kirillov, Lisbon, Portugal
– Prof. C. Nevado, Zurich, Switzerland
– Prof. T. Noël, Amsterdam, Netherlands
– Prof. G. Poli, Paris, France
– Prof. M. Schnürch, Wien, Austria
– Prof. F. Schoenebeck, Aachen, Germany
– Dr. J. Wencel-Delord, Strasbourg, France

4 industrial partners

Industrial Partners (4 PhD Positions):
– AstraZeneca, Sweden
– Novartis, Switzerland
– Syngenta, Switzerland
– ThalesNano, Hungary

2 industrial partner organizations

– Ingenhold-Boehringer, Austria
– Merck, Germany


AstraZeneca R&D Gothenburg, SWEDEN

AstraZeneca Gothenburg is one of AstraZeneca’s three global, strategic R&D centres. The site is home to expertise and capabilities across all areas of pharmaceutical development: from discovery science to the finished medicines used in clinical trials and ultimately by patients. Our proximity to bioscience clusters in Gothenburg, Gaithersburg and Cambridge are a key element in our work to achieve scientific leadership and to transform our culture and the way we carry out our science. Through our Gothenburg site we have strong links to important hospitals and research institutions in Sweden, across the Nordic region and beyond. In Sweden, our researchers work in close partnership with all the leading Swedish academic centres. Gothenburg benefits from its vicinity to the Sahlgrenska University Hospital, one of the largest hospitals in Europe, and its connections with, for example, the Karolinska Institute Main research of the Magnus J Johansson (MJJ) team focuses on different aspects of C–H functionalization in the drug discovery process with an emphasis on: (i) Late stage functionalization of advanced drug intermediates; (ii) utilization of modern synthesis methodology to optimize and make the drug discovery process more effective; (iii) methodology work in the field of metal catalyzed C–H activation.



Novartis is one of the world’s leading pharmaceutical companies with more than 120,000 employees worldwide. The mission of the organization is to use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. The organization pushes the boundaries of science in pursuit of medical breakthroughs both internally and externally via participation to such initiative as the Marie Curie Training Network..



Syngenta is one of the world’s leading companies with more than 28,000 employees in over 93 countries dedicated to their purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to their customers Syngenta helps to increase crop productivity, protect the environment and improve health and quality of life. With more than 5,000 R&D scientists worldwide and $1.5 billion invested annually in R&D, Syngenta strives to align their foundation with potential partners who share their vision. The company sees valuable opportunity in seeking innovative ideas outside its organization from all corners of the world, and hence their great interest in supporting this Marie Curie Training Network.


ThalesNano, Budapest, Hungary

ThalesNano is the world leader in bench-top flow chemistry reactors. The company has the widest portfolio of bench-top continuous process instruments for the pharmaceutical, biotech, fine chemical, petroleum/biofuel, and education markets. Its R&D 100 award winning H-Cube® and scale-up system H-Cube Midi™ are used in hundreds of laboratories globally and have become the new industry standard for hydrogenation. Within three years from the original introduction of its flagship H-Cube® product, 20 out of the top 20 pharmaceutical companies have adopted the technology.